TABLE 3

Serial testing of serum from PCR-positive casesa

SampleSex/age (yr)bCT valuePrimary vaccine seriesaP boostDate (mo/day/yr) of:Time from symptom onset to sampleACT ELISA (U/ml)TNA (%)dPT ELISA (U/ml)
Last vaccinationApprox symptom onsetc
V002AF/1426.35 aP+03/14/1108/25/142 wk 31.5 84.5 357
V002BF/14 8 wk 47.3 100 300
V002CF/15 16 mo 30.4 97.1 60.2
V003AM/17HCe5 aP+08/14/0809/15/144 wk 44.8 100 640
V003BM/17 10 wk 24.8 92.7 512
V003CM/18 17 mo3.59 1.3 110
V011AM/2234.53 wP, 2 aP+04/27/0707/31/155 days4.207.4
V011BM/22 4 wk 30.6 95.5 413
V011CM/22 4.5 mo 22.3 92.1 182
V015AF/1532.75 aP+08/07/1209/28/151 wk13.3 61.3 86.7
V015BF/15 5 wk 21.7 60.4 276
  • a Bolded values are considered positive (data for normal controls are given in Table 2). Data represent the mean of the results from each sample tested in duplicate (ELISA) or triplicate (TNA).

  • b F, female; M, male.

  • c At onset of clinical illness, all subjects reported symptoms consistent with pertussis.

  • d Percent toxin neutralization using a 1:50 final serum dilution, as described in Materials and Methods.

  • e HC, sample was from a household contact of subject V002 with clinical symptoms of pertussis.